{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041323","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.050411+00:00","generated_at":"2026-06-08T03:08:55.649565+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elite Pharma Q2 FY2024 revenue $14.2M (+64.9% YoY); net income $14.9M (+886%)","bullets":["Consolidated revenue of $14.2M for Q2 ended Sep 30, 2023, up 64.9% YoY.","Operating profit of $1.9M, up 78.1% from prior-year period.","Net income attributable to common shareholders: $14.9M, an 886% increase.","Growth driven by launch of Elite Laboratories label product line in June 2023 quarter.","Conference call scheduled for Nov 15, 2023 at 11:30 AM EST."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041323","json":"https://secwatch.observer/filing/0001493152-23-041323.json","markdown":"https://secwatch.observer/filing/0001493152-23-041323.md","text":"https://secwatch.observer/filing/0001493152-23-041323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223041323/0001493152-23-041323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223041323/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:08:55.649565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7341bc35d56502389972da017b7825f2990826a","claim":"ELITE PHARMACEUTICALS INC /NV/ reported the second quarter of fiscal year 2024 ended September 30, 2023 results: revenue $14.2 million, net income $14.9 million.","evidence_excerpt":"Consolidated revenues for the three-month period ended September 30, 2023, were $14.2 million, an increase of $5.6 million or 64.9% as compared to the comparable period of the prior fiscal year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223041323/0001493152-23-041323-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of fiscal year 2024 ended September 30, 2023"},{"label":"Revenue","value":"$14.2 million"},{"label":"Net income","value":"$14.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}